Ubs Asset Management Americas Inc Iveric Bio, Inc. Transaction History

Ubs Asset Management Americas Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$18.67 - $24.56 $7.09 Million - $9.32 Million	379,651 Added 317.97%	499,048 $12.1 Million
Q4 2022 Feb 14, 2023	BUY	$17.24 - $23.95 $148,091 - $205,730	8,590 Added 7.75%	119,397 $2.56 Million
Q3 2022 Nov 14, 2022	SELL	$9.4 - $18.59 $2,735 - $5,409	-291 Reduced 0.26%	110,807 $1.99 Million
Q2 2022 Aug 12, 2022	BUY	$9.12 - $18.9 $148,209 - $307,143	16,251 Added 17.13%	111,098 $1.07 Million
Q1 2022 May 16, 2022	BUY	$12.15 - $16.83 $218,614 - $302,822	17,993 Added 23.41%	94,847 $1.6 Million

Q4 2021 Feb 14, 2022	BUY	$13.83 - $18.78 $139,848 - $189,903	10,112 Added 15.15%	76,854 $1.28 Million
Q3 2021 Nov 15, 2021	SELL	$7.07 - $17.5 $103,914 - $257,215	-14,698 Reduced 18.05%	66,742 $1.08 Million
Q2 2021 Aug 16, 2021	BUY	$5.69 - $7.17 $14,731 - $18,563	2,589 Added 3.28%	81,440 $513,000
Q1 2021 May 14, 2021	BUY	$5.08 - $6.89 $108,971 - $147,797	21,451 Added 37.37%	78,851 $487,000
Q4 2020 Mar 01, 2021	BUY	$5.65 - $7.66 $324,310 - $439,684	57,400 New	57,400 $396,000

250K

40K

Ticker ISEE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,078,000
Description
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

Stay updated on Ubs Asset Management Americas Inc with notifications on news.